Navigation Links
International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
Date:7/19/2009

DETROIT, July 20 /PRNewswire-USNewswire/ -- Scientists at the Barbara Ann Karmanos Cancer Institute's National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) have discovered a probable reason for the unrelenting chest pain experienced in certain patients with asbestos-related diseases and cancers. The findings, featured in the July 20, 2009 edition of the International Journal of Occupational and Environmental Health, were published in an academic peer-reviewed manuscript by principal author Michael Harbut, M.D., MPH, co-director of the NCVAC and chief of the Center for Occupational and Environmental Medicine, affiliated with Wayne State University.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO)

Harbut reported the findings after studying a patient who was exposed to taconite dust as a child.

Using a new radiography approach developed by Carmen Endress, M.D., FACR, associate professor of Radiology, Wayne State University School of Medicine and radiologist at the NCVAC, there was a documented increase in pleural plaques, causing erosion on the interior wall of the ribs.

"This action of the pleural plaque against the covering of the bone and the bone itself is a biologically plausible and an anatomically logical explanation of the unrelenting pain which some patients experience," said Dr. Harbut.

This new imaging approach involves enhancing images obtained on the 64-slice high resolution CT scan using the Vitrea(R) imaging software program by Vital Images. By using this imaging approach, Dr. Harbut was able to demonstrate that:

  • Evidence based on the CT findings, the physical examination, pulmonary function studies, epidemiology and history of the patient's intractable pleural pain meets the criteria for diagnosis of asbestosis. Combined with the known science of taconite dust, a link between the mine where the patient's father worked and the patient's disease was established.
  • Due to the clarity and definition of this new imaging approach, it is more likely to detect asbestos-related diseases and cancer at an earlier stage.
  • Earlier detection will allow the possibility for additional treatment options to manage the pain caused by pleural plaque beyond the narcotics often prescribed for patients with advanced stages of asbestos disease. This includes exploring other forms of traditional and nontraditional methods to control pain.

The patient, studied since 2004 and currently 55 years of age, was exposed as a child to taconite dust unknowingly by her father, a taconite miner from 1962 - 1969, who carried the taconite dust on his work clothes. Taconite is used in the production of steel and road-patching material. It has been mined in Michigan and Minnesota.

The patient has experienced increasing pain on her right side for the past 31 years, a persistent cough and wheezing. As the pain increased so did her medication. Using the new imaging approach, Dr. Harbut was able to show the progression of the patient's pleural plaque over a three year period, from 2005 - 2008. The patient's pleuritic pain, as well as the findings of her pulmonary function, physical exam and symptomology are consistent with those diagnosed with asbestosis and pleural plaques, as established by the American Thoracic Society.

These findings also support earlier human and animal reports that dusts produced by taconite mining can evoke the same biological responses as do other fibers already defined as asbestos or asbestiform materials.

Harbut added, "Patients often require a lifetime of narcotics to allow functioning, but we are hopeful that with this new imaging technology, more selective pain management approaches with fewer side effects can be instituted resulting in a better quality of life."

Finally, the report supports the identification of taconite, which has not yet been categorized as asbestos but causes a disease consistent with asbestosis, and recommends a reevaluation of the definition of asbestos. This is especially important within the context of legislative efforts to prohibit the use of asbestos.

Karmanos scientists are continuing their series of patient studies and will submit similar findings for peer review later this summer.

In addition to Dr. Harbut, co-authors of the report include Carmen Endress, M.D., FACR; John J. Graff, Ph.D., MS, assistant professor, Wayne State University School of Medicine, and chief, Cancer Surveillance Research at the Barbara Ann Karmanos Cancer Institute; Christopher Weis, Ph.D., National Enforcement Investigations Center, United States Environmental Protection Agency; and Harvey Pass, M.D., director, New York University's Division of Thoracic Surgery.

About the National Center for Vermiculite and Asbestos-Related Cancers (NCVAC at Karmanos)

In response to the United States Environmental Protection Agency's (EPA) identification of major sources of public asbestos exposure in Michigan, and to address the need for early diagnosis and aggressive treatment of asbestos-related diseases, the Barbara Ann Karmanos Cancer Institute and the Center for Occupational and Environmental Medicine (COEM) affiliated with Wayne State University established Karmanos' National Center for Vermiculite and Asbestos-Related Cancers. The NCVAC is co-directed by Michael Harbut, M.D., MPH, Karmanos Cancer Institute and Chief of the Center for Occupational and Environmental Medicine; and John J. Graff, Ph.D. MS, chief of Cancer Surveillance Research, Karmanos Cancer Institute and assistant professor, Department of Family Medicine and Public Health Sciences, Wayne State University School of Medicine.

About Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/19/2017)... -- The Mobile X-Ray product segment is the most attractive ... forecast period Mobile X-Ray segment is the largest ... devices market, which is estimated to be valued at more ... of 7% over the forecast period. Mobile X-Ray segment is ... 100 Mn in 2017 over 2016. The segment,s revenue in ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
Breaking Medicine Technology:
(Date:4/25/2017)... CA (PRWEB) , ... April 25, 2017 , ... ... access, support, and collaboration, announces Mirroring360 Pro . This new addition to ... comprehensive collaboration experience for education and business. , Mirroring360 Pro enables educators, business ...
(Date:4/25/2017)... Indianapolis, IN (PRWEB) , ... April 25, 2017 ... ... Washington, D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration ... Life Financial will provide insight into what changes are most likely to make ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients ... that achieves results in a fraction of the time as traditional braces – ... Significance Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion ... head shops –can’t help but be heartened by the industry’s current surge. But another ... described as “skunk smell.” At last they can simply, safely and effectively end ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
Breaking Medicine News(10 mins):